Brief: Fusen Pharmaceutical Posts FY Profit Attributable RMB101.9 Mln
29/03/2019 15:47
March 29 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* RECOMMEND PAYMENT OF A FINAL DIVIDEND OF RMB0.74 CENTS PER
ORDINARY SHARE
* FY REVENUE RMB462.1 MILLION VERSUS RMB452.6 MILLION
* FY PROFIT ATTRIBUTABLE RMB101.9 MILLION VERSUS RMB96.8
MILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKS3TvxvK
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA